Is GLP-1 microdosing effective?

Clinical takeaway: Patients who remain on the lowest approved doses of semaglutide or tirzepatide for months may still experience modest weight loss, although the clinical benefits appear substantially smaller than those seen with standard dose escalation.

Interest in GLP-1 “microdosing” has grown as clinicians and patients navigate tolerability concerns, cost barriers, drug shortages, and individualized treatment goals. Yet virtually all evidence supporting semaglutide and tirzepatide comes from trials using recommended maintenance doses, leaving the effects of long-term non-escalation largely unexplored.

Researchers analyzed de-identified EHR data from nearly 29 million patients and identified 814 people who remained on semaglutide 0.25 mg only for at least 6 months and 1,016 who remained on tirzepatide 2.5 mg only. After matching, 534 patients in each group were compared.

Weight loss occurred in both cohorts but was greater with tirzepatide. At 12 months, patients receiving sustained low-dose tirzepatide lost an average of 5.5% of baseline body weight, compared with 2.2% for those receiving sustained low-dose semaglutide. By 6 months, average weight loss was 5.3% and 0.9%, respectively.

Notably, no significant differences emerged across 104 structured cardiometabolic, renal, hepatic, neurologic, pulmonary, or infectious-disease outcomes. However, note-based analyses suggested potentially higher rates of constipation (33% vs 22%), muscle cramps (8% vs 4%), dyspnea on exertion (10% vs 7%), and acute kidney injury (2.7% vs 0.4%) with low-dose tirzepatide, while semaglutide was associated with more diaphoresis (5.5% vs 3.2%) and ankle swelling (6.9% vs 3.7%). The authors emphasized that none of these adverse-event signals remained significant after adjustment for multiple comparisons and should be considered hypothesis-generating.

In a separate comparison, patients who stayed on low-dose semaglutide lost roughly 2% of body weight at 12 months versus 12% among matched patients escalated to higher doses, underscoring the tradeoff between effectiveness and tolerability.

“Our findings suggest that the effects of these therapies could emerge earlier on the dose-escalation curve than has been demonstrated to date,” the authors wrote, while noting that prospective studies are needed to determine whether GLP-1 microdosing is clinically useful or whether the findings are driven by characteristics of patients who do not escalate therapy.

Source: Murugadoss K, et al. (2026 Aug 31) Biol Methods Protoc. Comparison of Cardiometabolic Benefits and Tolerability in Patients on Sustained Low Doses of Semaglutide or Tirzepatide